TRPV4 neuromuscular disease registry highlights bulbar, skeletal and proximal limb manifestations
Brain · 2025
DOI: 10.1093/brain/awae201 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, 2025. Verfasst von Gage P Kosmanopoulos und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of Michigan Medical School, Ann Arbor, MI 48109, USA. Hauptthemen laut MEDLINE: TRPV Cation Channels, Charcot-Marie-Tooth Disease, Registries. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Office of Rare Diseases Research, NIH HHS, NINDS NIH HHS.
Abstract (Originalsprache)
Dominant missense mutations of the calcium-permeable cation channel TRPV4 cause Charcot-Marie-Tooth disease (CMT) type 2C and two forms of distal spinal muscular atrophy. These conditions are collectively referred to as TRPV4-related neuromuscular disease and share features of motor greater than sensory dysfunction and frequent vocal fold weakness. Pathogenic variants lead to gain of ion channel function that can be rescued by TRPV4 antagonists in cellular and animal models. As small molecule TRPV4 antagonists have proven safe in trials for other disease indications, channel inhibition is a promising therapeutic strategy for TRPV4 patients. However, the current knowledge of the clinical features and natural history of TRPV4-related neuromuscular disease is insufficient to enable rational clinical trial design. To address these issues, we developed a TRPV4 patient database and administered a TRPV4-specific patient questionnaire. Here, we report demographic and clinical information, including CMT Examination Scores (CMTES), from 68 patients with known pathogenic TRPV4 variants, 40 of whom also completed the TRPV4 patient questionnaire. TRPV4 patients showed a bimodal age of onset, with the largest peak occurring in the first 2 years of life. Compared to CMT type 1A (CMT1A) patients, TRPV4 patients showed distinct symptoms and signs, manifesting more ambulatory difficulties and more frequent involvement of proximal arm and leg muscles. Although patients reported fewer sensory symptoms, sensory dysfunction was often detected clinically. Many patients were affected by vocal fold weakness (55%) and shortness of breath (55%), and 11% required ventilatory support. Skeletal abnormalities were common, including scoliosis (64%), arthrogryposis (33%) and foot deformities. Strikingly, patients with infantile onset of disease showed less sensory involvement and less progression of symptoms. These results highlight distinctive clinical features in TRPV4 patients, including motor-predominant disease, proximal arm and leg weakness, severe ambulatory difficulties, vocal fold weakness, respiratory dysfunction and skeletal involvement. In addition, patients with infantile onset of disease appeared to have a distinct phenotype with less apparent disease progression based on CMTES. These collective observations indicate that clinical trial design for TRPV4-related neuromuscular disease should include outcome measures that reliably capture non-length dependent motor dysfunction, vocal fold weakness and respiratory disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
- Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
- Department of Neurology, Mass General Brigham, Boston, MA 02114, USA.
- Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA.
- Department of Neurology, University of Rochester, Rochester, NY 14627, USA.
- Department of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
ORCID-Profile: Mary M Reilly, Richard S Finkel, Davide Pareyson, Chiara Pisciotta, Brett A McCray
Förderung
- Office of Rare Diseases Research
- NIH HHS
- NINDS NIH HHS
- Rare Diseases Clinical Research Network
- Muscular Dystrophy Association
- INC
- NIH
- National Institute of Neurological Disorders and Stroke
Zitieren
APA
Kosmanopoulos, G. P., Donohue, J. K., Hoke, M., Thomas, S., Peyton, M. A., Vo, L., Crawford, T. O., Sadjadi, R., Herrmann, D. N., Yum, S. W., Reilly, M. M., Scherer, S. S., Finkel, R. S., Lewis, R. A., Pareyson, D., Pisciotta, C., Walk, D., Shy, M. E., Sumner, C. J., …, & McCray, B. A. (2025). TRPV4 neuromuscular disease registry highlights bulbar, skeletal and proximal limb manifestations. Brain. https://doi.org/10.1093/brain/awae201
Vancouver
Kosmanopoulos GP, Donohue JK, Hoke M, Thomas S, Peyton MA, Vo L, et al. TRPV4 neuromuscular disease registry highlights bulbar, skeletal and proximal limb manifestations. Brain. 2025. doi:10.1093/brain/awae201
BibTeX
@article{Kosmanopoulos2025,
author = {Kosmanopoulos, Gage P and Donohue, Jack K and Hoke, Maya and Thomas, Simone and Peyton, Margo A and Vo, Linh and Crawford, Thomas O and Sadjadi, Reza and Herrmann, David N and Yum, Sabrina W and Reilly, Mary M and Scherer, Steven S and Finkel, Richard S and Lewis, Richard A and Pareyson, Davide and Pisciotta, Chiara and Walk, David and Shy, Michael E and Sumner, Charlotte J and Inherited Neuropathies Consortium - Rare Disease Clinical Research Network, Inherited Neuropathies Consortium - Rare Disease Clinical Research Network and McCray, Brett A},
title = {TRPV4 neuromuscular disease registry highlights bulbar, skeletal and proximal limb manifestations},
journal = {Brain},
year = {2025},
doi = {10.1093/brain/awae201}
}
EUVIMED